Kerbs von Lungren 6 antigen is a marker of alveolar inflammation but not of infection in patients with acute respiratory distress syndrome

Critical Care

Volumn 12, Issue 1, 2008, Pages

  Nathani, Nazim ^a   Perkins, Gavin D ^b   Tunnicliffe, William ^c   Murphy, Nick ^c   Manji, Mav ^c   Thickett, David R ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GLYCOPROTEIN; INTERLEUKIN 8; KERBS VON LUNGREN 6 ANTIGEN; MYELOPEROXIDASE; UNCLASSIFIED DRUG; VASCULOTROPIN; CA 15-3 ANTIGEN; MUC1 PROTEIN, HUMAN;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIUM CULTURE; BLOOD SAMPLING; CELL COUNT; CLINICAL ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; EPITHELIUM CELL; FEMALE; HUMAN; LUNG ALVEOLUS; LUNG INFECTION; LUNG INJURY; LUNG LAVAGE; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; SCORING SYSTEM; BLOOD; BRONCHOSCOPY; CLASSIFICATION; CLINICAL TRIAL; HOSPITALIZATION; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PHYSIOLOGY; PNEUMONIA;

BIOLOGICAL MARKERS; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHOSCOPY; CA-15-3 ANTIGEN; FEMALE; HUMANS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PNEUMONIA; PROGNOSIS; RESPIRATORY DISTRESS SYNDROME, ADULT; SEVERITY OF ILLNESS INDEX;

EID: 41149127399     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc6785     Document Type: Article

References (18)

1. Sakao S Tatsumi K Hashimoto T Igari H Shino Y Shirasawa H Kuriyama T Vascular endothelial growth factor and the risk of smoking-related COPD Chest 2003, 124:323-327. 10.1378/chest.124.1.323 12853540
2. Uhal BD Rayford H Zhuang J Li X Laukka J Soledad-Conrad V Apoptosis-dependent acute lung injury and repair after intratracheal instillation of noradrenaline in rats Exp Physiol 2003, 88:269-275. 10.1113/eph8802523 12621532
3. Perkins GD Nathani N McAuley DF Gao F Thickett DR In vitro and in vivo effects of salbutamol on neutrophil function in acute lung injury Thorax 2007, 62:36-42. 10.1136/thx.2006.059410 16928710
4. Sinclair DG Braude S Haslam PL Evans TW Pulmonary endothelial permeability in patients with severe lung injury. Clinical correlates and natural history Chest 1994, 106:535-539. 10.1378/chest.106.2.535 7774333
5. Steinberg KP Milberg JA Martin TR Maunder RJ Cockrill BA Hudson LD Evolution of bronchoalveolar cell populations in the adult respiratory distress syndrome Am J Respir Crit Care Med 1994, 150:113-122. 8025736
6. Stahel RA Gilks WR Lehmann HP Schenker T Third International Workshop on Lung Tumor and Differentiation Antigens: Overview of the results of the central data analysis Int J Cancer Suppl 1994, 8:6-26. 10.1002/ ijc.2910570704 8194898
7. Kohno N Kyoizumi S Awaya Y Fukuhara H Yamakido M Akiyama M New serum indicator of interstitial pneumonitis activity. Sialylated carbohydrate antigen KL-6 Chest 1989, 96:68-73. 10.1378/chest.96.1.68 2661160
8. Ishizaka A Matsuda T Albertine KH Koh H Tasaka S Hasegawa N Kohno N Kotani T Morisaki H Takeda J Elevation of KL-6, a lung epithelial cell marker, in plasma and epithelial lining fluid in acute respiratory distress syndrome Am J Physiol Lung Cell Mol Physiol 2004, 286:L1088-L1094. 10.1152/ajplung.00420.2002 12959931
9. Kohno N Awaya Y Oyama T Yamakido M Akiyama M Inoue Y Yokoyama A Hamada H Fujioka S Hiwada K KL-6, a mucin-like glycoprotein, in bronchoalveolar lavage fluid from patients with interstitial lung disease Am Rev Respir Dis 1993, 148:637-642. 8368634
10. Inoue Y Barker E Daniloff E Kohno N Hiwada K Newman LS Pulmonary epithelial cell injury and alveolar-capillary permeability in berylliosis Am J Respir Crit Care Med 1997, 156:109-115. 9230733
11. Sato H Callister ME Mumby S Quinlan GJ Welsh KI duBois RM Evans TW KL-6 levels are elevated in plasma from patients with acute respiratory distress syndrome Eur Respir J 2004, 23:142-145. 10.1183/ 09031936.03.00070303 14738246
12. Bernard GR Artigas A Brigham KL Carlet J Falke K Hudson L Lamy M Legall JR Morris A Spragg R The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination Am J Respir Crit Care Med 1994, 149(3 Pt 1):818-824. 7509706
13. Stockley RA Bayley DL Validation of assays for inflammatory mediators in sputum Eur Respir J 2000, 15:778-781. 10.1034/j.1399-3003.2000.15d24.x 10780773
14. Luh SP Chiang CH Acute lung injury/acute respiratory distress syndrome (ALI/ARDS): The mechanism, present strategies and future perspectives of therapies J Zhejiang Univ Sci B 2007, 8:60-69. 1764923 17173364 10.1631/ jzus.2007.B0060
15. Ohnishi H Yokoyama A Kondo K Hamada H Abe M Nishimura K Hiwada K Kohno N Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases Am J Respir Crit Care Med 2002, 165:378-381. 11818324
16. Matthay MA New modes of mechanical ventilation for ARDS. How should they be evaluated? Chest 1989, 95:1175-1177. 10.1378/chest.95.6.1175 2721246
17. Perkins GD McAuley DF Thickett DR Gao F The beta-agonist lung injury trial (BALTI): A randomized placebo-controlled clinical trial Am J Respir Crit Care Med 2006, 173:281-287. 10.1164/rccm.200508-1302OC 16254268
18. Kase S Kitaichi N Namba K Miyazaki A Yoshida K Ishikura K Ikeda M Nakashima T Ohno S Elevation of serum Krebs von den Lunge-6 levels in patients with tubulointerstitial nephritis and uveitis syndrome Am J Kidney Dis 2006, 48:935-941. 10.1053/j.ajkd.2006.09.013 17162148